When it comes to site selection, Virginia offers many viable options for AstraZeneca to locate their $2 billion manufacturing facility.
August 21, 2025
When AstraZeneca announced plans this summer to pour $50 billion into its U.S. operations by 2030, headlines were quick to focus on the pharmaceutical giant’s decision to invest $2 billion to build a massive new drug substance manufacturing site in Virginia. Framed as the company’s largest single manufacturing investment worldwide, the move instantly elevated Virginia’s profile as a serious player in biopharma manufacturing.
Virginia has emerged as one of the most proactive states in building a biotech-friendly environment, committing more than $100 million in recent years through programs like GO Virginia, the Virginia Catalyst, and Activation Capital, alongside a $52.9 million federal Build Back Better award to accelerate pharmaceutical manufacturing. Last week Governor Glenn Youngkin announced the new Lab-to-Launch program, a first-of-its-kind, statewide commercialization effort designed to fast-track innovations from university labs into the marketplace.
From new lab accelerators in Charlottesville and Roanoke to major investments in Petersburg’s Alliance for Building Better Medicine, the Commonwealth is signaling to companies like AstraZeneca that it is all-in on life sciences growth and infrastructure.
So where, within the Commonwealth, does AstraZeneca stand to gain the most strategic advantage? Virginia offers a patchwork of life science hubs—from Richmond to Roanoke, Charlottesville to Coastal Virginia, and now Petersburg’s burgeoning manufacturing cluster. Each has its own assets, costs, and limitations. For AstraZeneca, choosing wisely could mean more than just logistics—it could reshape the regional balance of power in the Mid-Atlantic’s already competitive biotech landscape.
Richmond: The Historic Heart of Virginia Biotech
At the center of the state sits Richmond’s VA Bio+Tech Park, a 34-acre campus home to nearly 70 companies, research institutes, and labs that’s under the Activation Capital – a non-profit focused on developing the life sciences ecosystem in the Central Virginia region. Anchored by Virginia Commonwealth University (VCU) and the VCU Medical Center, Richmond’s biotech park offers wet-lab infrastructure, incubator support, and decades of institutional experience.
For AstraZeneca, Richmond brings one major advantage: a turnkey base for manufacturing scale-up. Its lower operating costs and mature facilities make it ideal for expanding commercial operations without the premiums of larger metros. Add in the city’s central location on the I-95 corridor, and Richmond emerges as a pragmatic option for anchoring large-scale production.
Petersburg: A New Model for Domestic Drug Manufacturing
Twenty-five miles south of Richmond, Petersburg has quickly become the poster child for reshoring pharmaceutical manufacturing. The city’s cluster includes Phlow, Civica, Novo Nordisk and AMPAC Fine Chemicals, all supported by the federally backed Alliance for Building Better Medicine. Together, these firms create an end-to-end ecosystem: from active pharmaceutical ingredients (APIs) to finished injectable drugs, including insulin.
This integrated model offers AstraZeneca something few regions can match: supply chain resilience. By plugging into Petersburg, the company could secure domestic access to critical raw materials and join a coalition already backed by federal investment. With the Port of Virginia nearby and competitive workforce costs, Petersburg positions itself as the state’s manufacturing crown jewel—a hub purpose-built for the very kinds of essential medicines AstraZeneca produces.
Northern Virginia: Policy, Talent, and Global Connectivity
On the other end of the spectrum lies Northern Virginia, better known for its tech corridors than its wet labs. Yet proximity to Washington, D.C., and Dulles International Airport brings unique advantages. For AstraZeneca, a Northern Virginia presence would offer unparalleled access to regulators and policymakers, as well as the region’s highly educated workforce and logistics.
Northern Virginia also provides very close proximity to AstraZeneca’s U.S. biologics headquarters, based in Gaithersburg, Maryland, where more than 3,000 employees drive research in oncology, cardiovascular, renal and metabolism, respiratory, and rare diseases. The company also operates a major cell therapy and advanced biologics manufacturing facility in Rockville, anchoring its presence in Maryland’s BioHealth Capital Region and positioning it among the state’s largest life science employers.
The trade-off is cost. With some of the highest living expenses in the Mid-Atlantic, Northern Virginia may not be ideal for manufacturing. But as a base for commercial operations, advanced analytics, or AI-driven R&D, it could extend AstraZeneca’s reach beyond the lab bench into the boardrooms shaping U.S. healthcare policy.
Charlottesville: A Rising Academic Powerhouse
In Charlottesville, AstraZeneca would find a hub defined by intellectual capital. The University of Virginia (UVA) and its affiliated health system fuel a vibrant ecosystem of over 75 biotech companies, many spun out of academic research. The city’s collaborative ethos, championed by CvilleBioHub, makes it attractive for discovery-driven R&D.
For AstraZeneca, Charlottesville would be less about immediate scale and more about long-term pipeline development—tapping into early-stage science and academic partnerships. With costs lower than Northern Virginia but a high density of talent, Charlottesville offers a strategic node for innovation.
Roanoke–Blacksburg: Translational Research in the Blue Ridge
Further southwest, the Roanoke–Blacksburg region is powered by Virginia Tech, the Fralin Biomedical Research Institute, and the Biocomplexity Institute. Areas of strength include genomics, infectious disease, and bioinformatics. While smaller in scale, the region has carved out a niche as a translational research hub, bridging fundamental science with practical applications.
If AstraZeneca were to diversify R&D beyond Maryland’s BioHealth Capital Region, Roanoke–Blacksburg could provide a foothold in emerging biomedical fields, at a fraction of the cost of coastal metros.
Coastal Virginia: Logistics and Global Reach
With direct access to the Port of Virginia, Coastal Virginia (Virginia Beach/Norfolk) offers AstraZeneca one thing no other hub can: seamless global logistics. For companies reliant on international supply chains and export markets, proximity to the port, coupled with rail, road, and air connections, creates a powerful distribution advantage.
While the region lacks the academic density of Charlottesville or the lab infrastructure of Richmond, it compensates with lower costs and logistical supremacy—an attractive complement for large-scale distribution and packaging operations.
The Virginia Equation: One State, Many Options
Unlike Maryland’s BioHealth Capital Region—which offers a dense, centralized cluster of federal labs, academic institutions, and industry—Virginia’s strength lies in its diversity. The Commonwealth provides AstraZeneca with a menu of options:
- Petersburg: Manufacturing scale and supply chain resilience.
- Richmond: Established biotech infrastructure with central access.
- Northern Virginia: Policy access and a highly educated workforce.
- Charlottesville: Academic partnerships and innovation.
- Roanoke–Blacksburg: Translational science and emerging biomedical research.
- Coastal Virginia: Distribution and global logistics.
The decision is less about choosing one hub than about designing the right portfolio. AstraZeneca could anchor manufacturing in Petersburg, tap Richmond for expansion capacity, leverage Charlottesville and Roanoke for discovery science, and use Northern and Coastal Virginia for policy and logistics.
For decades, AstraZeneca has been firmly rooted in Maryland’s Gaithersburg and Rockville clusters, embedded within the federal science ecosystem. But as the company expands its U.S. footprint, Virginia offers a complementary play: lower costs, resilient manufacturing, and a diversified hub network that can balance Maryland’s R&D concentration.
If AstraZeneca’s $50 billion bet is about more than scale—if it’s about resilience, balance, and future-proofing its supply chain—then Virginia is not just a site. It’s a strategic ecosystem, ready to meet the company where science, manufacturing, and policy converge.
